EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Effectiveness of Antiviral Prophylaxis for Preventing Hepatitis B Virus (HBV) Reactivation in Patients Undergoing Immunosuppressive Therapy

İnci Yılmaz Nakir iD, Bilge Çağlar iD, Esra Zerdali iD, Rumeysa Gülistan Karaduman iD, Filiz Pehlivanoğlu iD

Viruses · 2025

DOI: 10.3390/v17111436 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von İnci Yılmaz Nakir und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Haseki Training and Research Hospital, İstanbul 34096, Türkiye. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B virus, Virus Activation, Hepatitis B. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study evaluated the characteristics of patients receiving prophylactic antiviral therapy against hepatitis B virus (HBV) infection due to immunosuppressive treatment and assessed the occurrence of HBV reactivation. Between January 2015 and January 2025, 199 adult patients followed in the Infectious Diseases and Clinical Microbiology outpatient clinic who had received prophylactic oral antiviral therapy were retrospectively analyzed. Demographic characteristics, underlying diseases, immunosuppressive treatment history, HBV serological results, biochemical and virological findings, and prophylactic antiviral regimens were recorded. Patients were stratified into low-, moderate-, and high-risk groups according to the American Gastroenterological Association (AGA) 2025 classification. The mean age was 60.4 years; 50.3% of patients were male. Serologically, 26.6% were HBsAg- and anti-HBc-positive, 33.2% showed isolated anti-HBc positivity, and 40.2% had dual anti-HBc/anti-HBs positivity. The risk of HBV reactivation was low in 41.2%, moderate in 22.1%, and high in 36.7% of patients. Prophylaxis consisted of entecavir in 76.4%, tenofovir alafenamide in 13.1%, and tenofovir disoproxil fumarate in 10.5%. HBV reactivation occurred in only one patient, who had discontinued treatment. These findings emphasize the importance of HBV screening and timely prophylactic antiviral therapy in patients undergoing immunosuppression to effectively prevent HBV reactivation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis B virusVirus ActivationHepatitis BImmunosuppressive AgentsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultHepatitis B Antibodies

Stichwörter der Autor:innen

HBVentecavirimmunosuppressionreactivationtenofovir disoproxil fumarate

Substanzen

Antiviral AgentsImmunosuppressive AgentsHepatitis B Antibodies

Autor:innen und Institutionen

  • Department of Infectious Diseases and Clinical Microbiology, Haseki Training and Research Hospital, İstanbul 34096, Türkiye.

ORCID-Profile: İnci Yılmaz Nakir, Bilge Çağlar, Esra Zerdali, Rumeysa Gülistan Karaduman, Filiz Pehlivanoğlu

Zitieren

APA

Yılmaz Nakir, İ., Çağlar, B., Zerdali, E., Karaduman, R. G., & Pehlivanoğlu, F. (2025). Real-World Effectiveness of Antiviral Prophylaxis for Preventing Hepatitis B Virus (HBV) Reactivation in Patients Undergoing Immunosuppressive Therapy. Viruses. https://doi.org/10.3390/v17111436

Vancouver

Yılmaz Nakir İ, Çağlar B, Zerdali E, Karaduman RG, Pehlivanoğlu F. Real-World Effectiveness of Antiviral Prophylaxis for Preventing Hepatitis B Virus (HBV) Reactivation in Patients Undergoing Immunosuppressive Therapy. Viruses. 2025. doi:10.3390/v17111436

BibTeX
@article{YlmazNakir2025,
  author = {Yılmaz Nakir, İnci and Çağlar, Bilge and Zerdali, Esra and Karaduman, Rumeysa Gülistan and Pehlivanoğlu, Filiz},
  title = {Real-World Effectiveness of Antiviral Prophylaxis for Preventing Hepatitis B Virus (HBV) Reactivation in Patients Undergoing Immunosuppressive Therapy},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17111436}
}
Kostenlos starten →